Tirofiban and eptifibatide, but not abciximab, induce leukocyte-platelet aggregation

被引：0
|
作者：
Furman, MI
Krueger, LA
Frelinger , AL
Barnard, MR
Mascelli, MA
Nakada, MT
Michelson, AD
机构：
[1] Univ Massachusetts, Sch Med, Worcester, MA USA
[2] Centocor Inc, Malvern, PA USA
来源：
CIRCULATION | 1999年 / 100卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3591
引用
收藏
页码：681 / 681
页数：1
相关论文
共 50 条
  • [21] LEUKOCYTE-PLATELET AGGREGATION COUPLING AND ITS CHEMICAL MEDIATORS IN CEREBRAL-ISCHEMIA
    UCHIYAMA, S
    MOCHIZUKI, M
    BABAZONO, Y
    TEI, H
    KOBAYASHI, I
    MARUYAMA, S
    THROMBOSIS AND HAEMOSTASIS, 1991, 65 (06) : 773 - 773
  • [22] High Platelet Count in Platelet-Rich Plasma Reduces Measured Platelet Inhibition by Abciximab but not Tirofiban nor Eptifibatide Glycoprotein IIb/IIIa Receptor Antagonists
    Dean J. Kereiakes
    Thomas M. Broderick
    Eli M. Roth
    David Whang
    Michele Mueller
    Pam Lacock
    Linda C. Anderson
    Wendy Howard
    Chris Blanck
    John Schneider
    Charles A. Abbottsmith
    Journal of Thrombosis and Thrombolysis, 2000, 9 : 149 - 155
  • [23] High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists
    Kereiakes, DJ
    Broderick, TM
    Roth, EM
    Whang, D
    Mueller, M
    Lacock, P
    Anderson, LC
    Howard, W
    Blanck, C
    Schneider, J
    Abbottsmith, CA
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2000, 9 (02) : 149 - 155
  • [24] Combined effects of mild hypothermia and glycoprotein IIb/IIIa antagonists on platelet-platelet and leukocyte-platelet aggregation
    Frelinger, AL
    Furman, MI
    Barnard, MR
    Krueger, LA
    Dae, MW
    Michelson, AD
    AMERICAN JOURNAL OF CARDIOLOGY, 2003, 92 (09) : 1099 - 1101
  • [25] In vitro effects of the glycoprotein IIb/IIIa receptor antagonists abciximab and eptifibatide on platelet aggregation in healthy cats
    Magee, Aliya N.
    Hogan, Daniel E.
    Sederquist, Kimberly A.
    Durham, Jaylyn A.
    AMERICAN JOURNAL OF VETERINARY RESEARCH, 2014, 75 (03) : 309 - 312
  • [26] Randomized COMparison of platelet inhibition with abciximab, TiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes - The COMPARE trial
    Batchelor, WB
    Tolleson, TR
    Huang, Y
    Larsen, RL
    Mantell, RM
    Dillard, P
    Davidian, M
    Zhang, DW
    Cantor, WJ
    Sketch, MH
    Ohman, EM
    Zidar, JP
    Gretler, D
    DiBattiste, PM
    Tcheng, JE
    Califf, RM
    Harrington, RA
    CIRCULATION, 2002, 106 (12) : 1470 - 1476
  • [27] The significance of leukocyte-platelet aggregates formation by platelet activation
    Nagasawa, A.
    Tamura, S.
    Hayasaka, K.
    Moriyama, T.
    Matsuno, K.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 536 - 536
  • [28] EFFECTS OF DIPYRIDAMOLE ON LEUKOCYTE-PLATELET INTERACTIONS
    TREMOLI, E
    MADERNA, P
    ELIGINI, S
    COLLI, S
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 183 (02) : 637 - 637
  • [29] Compatibility of argatroban with abciximab, eptifibatide, or tirofiban during simulated Y-site administration
    Patel, K
    Hursting, MJ
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2005, 62 (13) : 1381 - 1384
  • [30] The Benefits and Risks of Abciximab, Eptifibatide, or Tirofiban During PCI: Class Effects or Do They Differ?
    Zijistra, Felix
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2009, 73 (02) : 222 - 223
12345